Literature DB >> 26040660

Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys.

Sandrine Marchand1,2,3, Salim Bouchene4, Michèle de Monte5, Laurent Guilleminault5, Jérôme Montharu5, Maria Cabrera5, Nicolas Grégoire6,7, Patrice Gobin6,8, Patrice Diot5, William Couet6,7,8, Laurent Vecellio5.   

Abstract

PURPOSE: The objective of this study was to compare two different nebulizers: Eflow rapid® and Pari LC star® by scintigraphy and PK modeling to simulate epithelial lining fluid concentrations from measured plasma concentrations, after nebulization of CMS in baboons.
METHODS: Three baboons received CMS by IV infusion and by 2 types of aerosols generators and colistin by subcutaneous infusion. Gamma imaging was performed after nebulisation to determine colistin distribution in lungs. Blood samples were collected during 9 h and colistin and CMS plasma concentrations were measured by LC-MS/MS. A population pharmacokinetic analysis was conducted and simulations were performed to predict lung concentrations after nebulization.
RESULTS: Higher aerosol distribution into lungs was observed by scintigraphy, when CMS was nebulized with Pari LC® star than with Eflow Rapid® nebulizer. This observation was confirmed by the fraction of CMS deposited into the lung (respectively 3.5% versus 1.3%).CMS and colistin simulated concentrations in epithelial lining fluid were higher after using the Pari LC star® than the Eflow rapid® system.
CONCLUSIONS: A limited fraction of CMS reaches lungs after nebulization, but higher colistin plasma concentrations were measured and higher intrapulmonary colistin concentrations were simulated with the Pari LC Star® than with the Eflow Rapid® system.

Entities:  

Keywords:  colistin; nebulization; pharmacokinetic modelling; scintigraphy

Mesh:

Substances:

Year:  2015        PMID: 26040660     DOI: 10.1007/s11095-015-1716-0

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  60 in total

1.  Comparison of lung deposition of colomycin using the HaloLite and the Pari LC Plus nebulisers in patients with cystic fibrosis.

Authors:  N M Byrne; P M Keavey; J D Perry; F K Gould; D A Spencer
Journal:  Arch Dis Child       Date:  2003-08       Impact factor: 3.791

Review 2.  The use of intravenous and aerosolized polymyxins for the treatment of infections in critically ill patients: a review of the recent literature.

Authors:  Matthew E Falagas; Sofia K Kasiakou; Sotirios Tsiodras; Argyris Michalopoulos
Journal:  Clin Med Res       Date:  2006-06

3.  Consistent global approach on reporting of colistin doses to promote safe and effective use.

Authors:  Roger L Nation; Jian Li; Otto Cars; William Couet; Michael N Dudley; Keith S Kaye; Johan W Mouton; David L Paterson; Vincent H Tam; Ursula Theuretzbacher; Brian T Tsuji; John D Turnidge
Journal:  Clin Infect Dis       Date:  2013-10-08       Impact factor: 9.079

4.  Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study.

Authors:  I P Korbila; A Michalopoulos; P I Rafailidis; D Nikita; G Samonis; M E Falagas
Journal:  Clin Microbiol Infect       Date:  2009-09-02       Impact factor: 8.067

5.  Microdialysis study of cefotaxime cerebral distribution in patients with acute brain injury.

Authors:  Claire Dahyot-Fizelier; Denis Frasca; Nicolas Grégoire; Christophe Adier; Olivier Mimoz; Bertrand Debaene; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2013-04-09       Impact factor: 5.191

6.  Aerosol deposition in neonatal ventilation.

Authors:  Jean C Dubus; Laurent Vecellio; Michele De Monte; James B Fink; Daniel Grimbert; Jerome Montharu; Chantal Valat; Neil Behan; Patrice Diot
Journal:  Pediatr Res       Date:  2005-03-17       Impact factor: 3.756

7.  Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models.

Authors:  Rajesh V Dudhani; John D Turnidge; Kingsley Coulthard; Robert W Milne; Craig R Rayner; Jian Li; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2009-12-22       Impact factor: 5.191

8.  Quantitative deposition of aerosolized gentamicin in cystic fibrosis.

Authors:  J S Ilowite; J D Gorvoy; G C Smaldone
Journal:  Am Rev Respir Dis       Date:  1987-12

Review 9.  Early antibiotic treatment of pseudomonas aeruginosa colonisation in cystic fibrosis: a critical review of the literature.

Authors:  Federico Marchetti; Luisella Giglio; Manila Candusso; Dino Faraguna; Baroukh M Assael
Journal:  Eur J Clin Pharmacol       Date:  2004-03-05       Impact factor: 2.953

10.  Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Timothy C Smeaton; Kingsley Coulthard
Journal:  J Antimicrob Chemother       Date:  2004-03-24       Impact factor: 5.790

View more
  8 in total

1.  Substantial Targeting Advantage Achieved by Pulmonary Administration of Colistin Methanesulfonate in a Large-Animal Model.

Authors:  Cornelia B Landersdorfer; Tri-Hung Nguyen; Linh Thuy Lieu; Gary Nguyen; Robert J Bischof; Els N Meeusen; Jian Li; Roger L Nation; Michelle P McIntosh
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

2.  Pulmonary Pharmacokinetics of Colistin following Administration of Dry Powder Aerosols in Rats.

Authors:  Yu-Wei Lin; Qi Tony Zhou; Yang Hu; Nikolas J Onufrak; Siping Sun; Jiping Wang; Alan Forrest; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2017-10-24       Impact factor: 5.191

Review 3.  Inhaled Antibiotics for Gram-Negative Respiratory Infections.

Authors:  Eric Wenzler; Dustin R Fraidenburg; Tonya Scardina; Larry H Danziger
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

4.  Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model.

Authors:  Yu-Wei Lin; Qi Tony Zhou; Mei-Ling Han; Ke Chen; Nikolas J Onufrak; Jiping Wang; John D Turnidge; Benjamin P Howden; Alan Forrest; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

5.  Evaluation of co-delivery of colistin and ciprofloxacin in liposomes using an in vitro human lung epithelial cell model.

Authors:  Guihong Chai; Heejun Park; Shihui Yu; Fanfan Zhou; Jian Li; Qingguo Xu; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2019-08-12       Impact factor: 5.875

6.  Aerosolized Polymyxin B for Treatment of Respiratory Tract Infections: Determination of Pharmacokinetic-Pharmacodynamic Indices for Aerosolized Polymyxin B against Pseudomonas aeruginosa in a Mouse Lung Infection Model.

Authors:  Yu-Wei Lin; Qi Zhou; Nikolas J Onufrak; Veronika Wirth; Ke Chen; Jiping Wang; Alan Forrest; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2017-07-25       Impact factor: 5.191

7.  Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model.

Authors:  Yu-Wei Lin; Qi Tony Zhou; Mei-Ling Han; Nikolas J Onufrak; Ke Chen; Jiping Wang; Alan Forrest; Hak-Kim Chan; Jian Li
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 8.  Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: Historical Background, Pharmacokinetics and Perspectives.

Authors:  Yinggang Zhu; Antoine Monsel; Jason A Roberts; Konstantinos Pontikis; Olivier Mimoz; Jordi Rello; Jieming Qu; Jean-Jacques Rouby
Journal:  Microorganisms       Date:  2021-05-27
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.